GTx-027

GTx-027 is an orally active and non-steroidal selective androgen receptor modulator (SARM) . GTx-027 shows androgen receptor (AR) transactivation effects with the EC50 of 1.8 nM. GTx-027 acts selectively increase muscle weight (anabolic) without affecting secondary sexual organs (androgenic) . GTx-027 has the protential for the study of breast cancer and stress urinary incontinence (SUI) [1][2].

Product Specifications

CAS Number

[928122-40-1]

UNSPSC

12352005

Target

Androgen Receptor

Related Pathways

Vitamin D Related/Nuclear Receptor

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cancer; Endocrinology

Purity

99.61

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

N#CC(C=C1)=CC=C1OC[C@](C)(O)C(NC2=CC(Cl)=C(C=C2)C#N)=O

Molecular Formula

C18H14ClN3O3

Molecular Weight

355.78

References & Citations

[1]Suriyan Ponnusamy, et al. Tissue Selective Androgen Receptor Modulators (SARMs) Increase Pelvic Floor Muscle Mass in Ovariectomized Mice. J Cell Biochem. 2017 Mar;118 (3) :640-646.|[2]Narayanan R, et al. Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signaling. PLoS One. 2014 Jul 29;9 (7) :e103202.